



A Clinical Trial for
non-small cell
lung cancer (NSCLC)

Have you been diagnosed with non-small cell lung cancer (NSCLC)?

You may be able to join a clinical trial for people with
a certain type of NSCLC.

What is the goal of this trial?

The goal of this trial is to learn if an investigational trial drug combination, MK-2870 combined with pembrolizumab, given after treatment with chemotherapy and pembrolizumab may help stop or slow down the spread of the cancer. All participants will first receive chemotherapy and pembrolizumab. This trial will then compare the investigational combination of MK-2870 plus pembrolizumab to pembrolizumab given alone.

Can I join this clinical trial?

You may be able to join if you have squamous NSCLC that has spread to other parts of your body. Trial staff will do tests to see if you meet the requirements to be able to join the trial.

To learn more about this study, such as who can join,
and the possible risks and benefits of joining, you can:

Talk to your doctor

Contact Merck by

Visiting
www.merckoncologyclinicaltrials.com

Scanning this QR code:

